Garland joins Exelixis

Tuesday, October 25, 2011 12:52 PM

Exelixis has named J. Scott Garland as executive vice president and chief commercial officer. As the company's chief commercial officer, Gardland will oversee the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

Garland comes to Exelixis from Genentech, where he served as vice president of its Avastin franchise. Prior to that position, he served as vice president, hematology marketing and sales, overseeing the Rituxan franchise and as a director on the Tarceva franchise.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs